Search

Boehringer Ingelheim to Acquire NBE-Therapeutics for EUR 1.18 Billion, Significantly Enhancing Its Cancer Pipeline Portfolio with Novel Antibody-Drug Conjugates

From garage start-up to global pharma: combining strengths to advance regenerative medicine

Article describing how a strategic partnership between Global Stem Cell and Boehringer Ingelheim Animal Health has played a key role in helping the companies accelerate breakthroughs in regenerative medicine.

BI Launches Vaccine to Protect Poultry | Boehringer Ingelheim US

Read more on the Boehringer Ingelheim launched Animal Health vaccine, aimed at protecting poultry from three different diseases.

Larry's Story: The Power of Patient Advocacy

For Larry, patient advocacy is an important part of his cancer journey. Learn more about Larry and his role with GO2 for Lung Cancer.

Boehringer Ingelheim and University of Dundee Highlight Successful PROTAC Drug Discovery Program and Extend Their Ongoing Anti-Cancer Alliance

Fremont, California

Boehringer Ingelheim’s Fremont, California facility in the San Francisco Bay

NVSS: The Future Vets & Scientists | Boehringer Ingelheim US

Click here to read more on the annual National Veterinary Scholars Symposium, celebrating future veterinarians and scientists across the USA.

HBA Rising Star & Luminary Awards | Boehringer Ingelheim US

Read more on the HBA, is a global nonprofit organization recognizing outstanding individuals and companies who impact and influence women in healthcare.

Recognized as an inclusive workplace for the fifth time

Recognized as an Inclusive Workplace for the Fifth Time

BI USA Recognized as Best Place to Work for LGBTQ+ Equality

About our Innovation Prize

Established in 2015 and jointly sponsored by BI and the BI Venture Fund, the prize allows recipients to focus on development of breakthrough medicines.

Swine Vaccine Combo for Two Diseases | Boehringer Ingelheim US

Click here to read more on the launch of the Boehringer Ingelheim innovative vaccine combination, protecting US swine from two viruses in one shot.

Reducing Stress in Horses – With Music

Click here to read more on the release of the Boehringer Ingelheim specially composed music track, designed to keep horses safe and "sound".

Boehringer Ingelheim acquires Abexxa Biologics to further expand its research efforts in cancer immunology and novel immunotherapeutic approaches

Sanofi and Boehringer Ingelheim confirm Closing of business swap on January 1st 2017

Making Toys for Shelter Animals | Boehringer Ingelheim US

Find out how nearly 400 Boehringer Ingelheim employees came together to make toys out of donated t-shirts for animals living in shelters across the USA.

Accountability, Agility, Intrapreneurship

How we work together

Boehringer Ingelheim Office Hours

An Employee’s Commitment to Ensuring Access to Medicines

Kobe

The Kobe Pharma Research Institute takes part in the global research and development activities for human pharmaceuticals.

Building Successful Partnerships in Animal Health

Christoph Vetten, Head of Transactions Animal Health, shares his perspectives on how building successful collaborations can drive innovation.

Boehringer Ingelheim and Oxford BioTherapeutics Expand Collaboration to Discover Novel Selective Tumor Targets as First Bispecific Antibody Advanced into the Clinic

Meet our 2023 HBA Luminary award winner honored for inspiring others

Leadership insights about our focus on patient centricity

Read about our patient-centric approach in discovering and developing medicines that transform patients’ lives from the point of view of Keri Yale, our head of patient centricity and engagement

Fighting Non-Communicable Diseases | Boehringer Ingelheim US

Read more on Boehringer Ingelheim's new NCD initiative, aiming to reduce NCD prevalence and capture the impact of our product portfolio for our patients.

About Us

Human Health

Animal Health

Science & Innovation

Partnering

Careers